Pathophysiology of Diabetic Dyslipidemia
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Abstract
Accumulating clinical evidence has suggested serum triglyceride (TG) is a leading predictor of atherosclerotic cardiovascular disease, comparable to low-density lipoprotein (LDL)-cholesterol (C) in populations with type 2 diabetes, which exceeds the predictive power of hemoglobinA1c. Atherogenic dyslipidemia in diabetes consists of elevated serum concentrations of TG-rich lipoproteins (TRLs), a high prevalence of small dense low-density lipoprotein (LDL), and low concentrations of cholesterol-rich high-density lipoprotein (HDL)2-C. A central lipoprotein abnormality is an increase in large TG-rich very-low-density lipoprotein (VLDL)1, and other lipoprotein abnormalities are metabolically linked to increased TRLs. Insulin critically regulates serum VLDL concentrations by suppressing hepatic VLDL production and stimulating VLDL removal by activation of lipoprotein lipase. It is still debated whether hyperinsulinemia compensatory for insulin resistance is causally associated with the overproduction of VLDL. This review introduces experimental and clinical observations revealing that insulin resistance, but not hyperinsulinemia stimulates hepatic VLDL production. LDL and HDL consist of heterogeneous particles with different size and density. Cholesterol-depleted small dense LDL and cholesterol-rich HDL2 subspecies are particularly affected by insulin resistance and can be named "Metabolic LDL and HDL," respectively. We established the direct assays for quantifying small dense LDL-C and small dense HDL(HDL3)-C, respectively. Subtracting HDL3-C from HDL-C gives HDL2-C. I will explain clinical relevance of measurements of LDL and HDL subspecies determined by our assays. Diabetic kidney disease (DKD) substantially worsens plasma lipid profile thereby potentiated atherogenic risk. Finally, I briefly overview pathophysiology of dyslipidemia associated with DKD, which has not been so much taken up by other review articles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, the activation of PPARα reduces small dense LDL particles by (1) producing apo C-III-poor VLDL particles that interacts less well CETP and (2) increasing the formation of large buoyant LDL that has a high affinity to and are easily taken up by LDL receptor.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Non-elevated LDL cholesterol values together with higher triglycerides and lower HDL-cholesterol are common in patients with abdominal obesity, T2D, and metabolic syndrome (61, 62); these individuals often still have elevated atherogenic lipoproteins such as non-HDL (63), small LDL particles (62, 64), and VLDL (62, 64).”
From Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial (2019) · cites this paper as [64]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Cholesterol accumulation in the brain, particularly in astrocytes, contributes to this pathological process.”
From Cholesterol-driven pathological astrocytic responses in diabetes-associated cognitive impairment through astrocytic SCAP accumulation and NF-κB–C3 signaling modulation (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411
Lewis, G. F., Carpentier, A., Adeli, K., & Giacca, A. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0461 · Cited by 1,333
Stampfer, M. J. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540110036029 · Cited by 1,079
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
Goldberg, I. J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37569-6 · Cited by 1,010
Metabolic origins and clinical significance of LDL heterogeneity
Berneis, K. K., & Krauss, R. M. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200004-jlr200 · Cited by 896
Diabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
Adiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820
Pathophysiology of diabetic dyslipidaemia: where are we?
Vergès, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3525-8 · Cited by 708
Transcriptional regulation of hepatic lipogenesis
Wang, Y., Viscarra, J., Kim, S.-J., & Sul, H. S. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4074 · Cited by 646
Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
Hoogeveen, R. C., Gaubatz, J. W., Sun, W., Dodge, R. C., Crosby, J. R., Jiang, J., Couper, D., Virani, S. S., Kathiresan, S., Boerwinkle, E., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303284 · Cited by 507
Lewis, G. F., Uffelman, K. D., Szeto, L. W., Weller, B., & Steiner, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117633 · Cited by 502
Brunzell, J. D., Hazzard, W. R., Porte, D., & Bierman, E. L. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107334 · Cited by 484
Biddinger, S. B., Hernandez-Ono, A., Rask-Madsen, C., Haas, J. T., Alemán, J. O., Suzuki, R., Scapa, E. F., Agarwal, C., Carey, M. C., Stephanopoulos, G., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.013 · Cited by 469
Dixon, J. L., Furukawa, S., & Ginsberg, H. N. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)67758-6 · Cited by 418
Nakajima, K., Saito, T., Tamura, A., Suzuki, M., Nakano, T., Adachi, M., Tanaka, A., Tada, N., Nakamura, H., Campos, E., et al. (1993) · Clinica Chimica Acta · doi:10.1016/0009-8981(93)90062-9 · Cited by 416
Ota, T., Gayet, C., & Ginsberg, H. N. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32752 · Cited by 376
Dixon, J., & Ginsberg, H. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40744-8 · Cited by 368
Kathiresan, S., Otvos, J. D., Sullivan, L. M., Keyes, M. J., Schaefer, E. J., Wilson, P. W. F., D’Agostino, R. B., Vasan, R. S., & Robins, S. J. (2006) · Circulation · doi:10.1161/circulationaha.105.567107 · Cited by 318
Foxo1 mediates insulin action on apoC-III and triglyceride metabolism
Altomonte, J., Lin, C., Harbaran, S., Richter, A. M., Xu, J., Meseck, M. L., & Dong, H. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19992 · Cited by 309
Pykälistö, O. J., Smith, P. H., & Brunzell, J. D. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108185 · Cited by 285
Li, W. W., Dammerman, M. M., Smith, J. D., Metzger, S., Breslow, J. L., & Leff, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118324 · Cited by 278
Barrows, B. R., & Parks, E. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1709 · Cited by 272
The U.K. Prospective Diabetes Study. A review
Turner, R. C. (1998) · Diabetes Care · doi:10.2337/diacare.21.3.c35 · Cited by 267
Cohn, J. S., Johnson, E. J., Millar, J. S., Cohn, S. D., Milne, R. W., Marcel, Y. L., Russell, R. M., & Schaefer, E. J. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)35345-1 · Cited by 248
Diabetic Lipemia: A Form of Acquired Fat-Induced Lipemia
Bagdade, J. D., Porte, D., & Bierman, E. L. (1967) · New England Journal of Medicine · doi:10.1056/nejm196702232760802 · Cited by 248
Okazaki, M., Usui, S., Ishigami, M., Sakai, N., Nakamura, T., Matsuzawa, Y., & Yamashita, S. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000155017.60171.88 · Cited by 228
Durrington, P. N., Newton, R. S., Weinstein, D. B., & Steinberg, D. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110604 · Cited by 215
Diabetic Hypertriglyceridemia: Evidence for Three Clinical Syndromes
Reaven, G. M., & Greenfield, M. S. (1981) · Diabetes · doi:10.2337/diab.30.2.s66 · Cited by 212
Sone, H., Tanaka, S., Tanaka, S., Iimuro, S., Oida, K., Yamasaki, Y., Oikawa, S., Ishibashi, S., Katayama, S., Ohashi, Y., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0622 · Cited by 201
Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523219 · Cited by 201
A novel and simple method for quantification of small, dense LDL
Hirano, T., Ito, Y., Saegusa, H., & Yoshino, G. (2003) · Journal of Lipid Research · doi:10.1194/jlr.d300007-jlr200 · Cited by 192
Self-citationBoström, K., Wettesten, M., Borén, J., Bondjers, G., Wiklund, O., & Olofsson, S. O. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67090-5 · Cited by 191
Davis, R. A., Thrift, R. N., Wu, C. C., & Howell, K. E. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38770-8 · Cited by 191
Postprandial hypertriglyceridemia as a coronary risk factor
Borén, J., Matikainen, N., Adiels, M., & Taskinen, M.-R. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.015 · Cited by 182
Development of a Homogeneous Assay for Measurement of Small Dense LDL Cholesterol
Ito, Y., Fujimura, M., Ohta, M., & Hirano, T. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.149559 · Cited by 181
Self-citationMetabolic Basis of Hypotriglyceridemic Effects of Insulin in Normal Men
Malmström, R., Packard, C. J., Watson, T. D. G., Rannikko, S., Caslake, M., Bedford, D., Stewart, P., Yki-Järvinen, H., Shepherd, J., & Taskinen, M.-R. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.7.1454 · Cited by 177
Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome
Clement, L. C., Macé, C., Avila-Casado, C., Joles, J. A., Kersten, S., & Chugh, S. S. (2014) · Nature Medicine · doi:10.1038/nm.3396 · Cited by 173
Pennacchio, L. A., & Rubin, E. M. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054194.78240.45 · Cited by 168
Davis, H. R., & Veltri, E. P. (2007) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14.99 · Cited by 160
Lee, E.-C., Desai, U., Gololobov, G., Hong, S., Feng, X., Yu, X.-C., Gay, J., Wilganowski, N., Gao, C., Du, L.-L., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807899200 · Cited by 151
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
Voight, B. F., Peloso, G. M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M. K., Hindy, G., Hólm, H., Ding, E. L., Johnson, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60312-2 · Cited by 148
Reaven, G. M. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.12.001 · Cited by 146
Lally, S., Tan, C. Y., Owens, D., & Tomkin, G. (2006) · Diabetologia · doi:10.1007/s00125-006-0177-8 · Cited by 146
Arai, H., Kokubo, Y., Watanabe, M., Sawamura, T., Ito, Y., Minagawa, A., Okamura, T., & Miyamato, Y. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14936 · Cited by 146
Karpe, F., Bell, M., Björkegren, J., & Hamsten, A. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.2.199 · Cited by 143
Kubota, N., Kubota, T., Kajiwara, E., Iwamura, T., Kumagai, H., Watanabe, T., Inoue, M., Takamoto, I., Sasako, T., Kumagai, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms12977 · Cited by 143
Apolipoprotein A-V-heparin Interactions
Lõokene, A., Beckstead, J. A., Nilsson, S., Olivecrona, G., & Ryan, R. O. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501589200 · Cited by 135
Schaefer, E. J., McNamara, J. R., Shah, P. K., Nakajima, K., Cupples, L. A., Ordovás, J. M., & Wilson, P. W. F. (2002) · Diabetes Care · doi:10.2337/diacare.25.6.989 · Cited by 135
Vedala, A., Wang, W., Neese, R. A., Christiansen, M. P., & Hellerstein, M. K. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600200-jlr200 · Cited by 131
Hirano, T., Ito, Y., Koba, S., Toyoda, M., Ikejiri, A., Saegusa, H., Yamazaki, J., & Yoshino, G. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000117179.92263.08 · Cited by 130
Self-citationApolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease
Kohan, A. B. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000136 · Cited by 128
FoxO1 integrates insulin signaling to VLDL production.
Kamagate, A., & Dong, H. H. (2008) · Cell Cycle · doi:10.4161/cc.7.20.6882 · Cited by 127
Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease
Srivastava, R. A. K. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3165-z · Cited by 125
Phung, T. L., Roncone, A. M., Jensen, K. L. D. M., Sparks, C. E., & Sparks, J. D. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.49.30693 · Cited by 122
Dissociation of apoprotein B and triglyceride production in very-low-density lipoproteins
Melish, J. S., Le, N., Ginsberg, H. N., Steinberg, D. H., & Brown, W. V. (1980) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1980.239.5.e354 · Cited by 121
Allister, E. M., Borradaile, N. M., Edwards, J. Y., & Huff, M. W. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1676 · Cited by 116
Sparks, C. E., Sparks, J. D., Bolognino, M., Salhanick, A. I., Strumph, P., & Amatruda, J. M. (1986) · Metabolism · doi:10.1016/0026-0495(86)90026-0 · Cited by 114
Duez, H., Lamarche, B., Valéro, R., Pavlic, M., Proctor, S. D., Xiao, C., Szeto, L., Patterson, B. W., & Lewis, G. F. (2008) · Circulation · doi:10.1161/circulationaha.107.739888 · Cited by 114
Škrha, J., Haas, T., Šindelka, G., Prázný, M., Widimský, J., Cibula, D., & Svačina, Š. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-030024 · Cited by 108
Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes
Vergès, B. L. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.01.028 · Cited by 106
Hiukka, A., Fruchart‐Najib, J., Leinonen, E. S., Hilden, H., Fruchart, J., & Taskinen, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1753-z · Cited by 104
Zhang, Y., Hernández‐Ono, A., Ko, C., Yasunaga, K., Huang, L., & Ginsberg, H. N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400220200 · Cited by 97
Effects of pioglitazone on lipid and lipoprotein metabolism.
Betteridge, D. J. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00715.x · Cited by 91
Gill, J. M. R., Brown, J. C., Bedford, D. K., Wright, D. M., Cooney, J., Hughes, D. A., Packard, C. J., & CASLAKE, M. J. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.04.022 · Cited by 88
Maeda, S., Nakanishi, S., Yoneda, M., Awaya, T., Yamane, K., Hirano, T., & Kohno, N. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11445 · Cited by 81
Self-citationWu, X., Sakata, N., Dixon, J. L., & Ginsberg, H. N. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39963-6 · Cited by 77
Adiels, M., Matikainen, N., Westerbacka, J., Söderlund, S., Larsson, T. P., Olofsson, S., Borén, J., & Taskinen, M. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.02.001 · Cited by 68
Mechanism of intestinal lipoprotein overproduction in insulin resistant humans
Duez, H., Pavlic, M., & Lewis, G. F. (2008) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2008.05.013 · Cited by 67
New and emerging regulators of intestinal lipoprotein secretion
Xiao, C., Dash, S., Morgantini, C., & Lewis, G. F. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.047 · Cited by 62
Abnormal lipoprotein metabolism in diabetic nephropathy
Hirano, T. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0880-y · Cited by 61
Self-citationHirano, T., Sakaue, T., Misaki, A., Murayama, S., Takahashi, T., Okada, K., Takeuchi, H. T., Yoshino, G., & Adachi, M. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00019.x · Cited by 57
Self-citationKageyama, H., Hirano, T., Okada, K., Ebara, T., Kageyama, A., Murakami, T., Shioda, S., & Adachi, M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00663-6 · Cited by 56
Self-citationOi, K., Hirano, T., Sakai, S., Kawaguchi, Y., & Hosoya, T. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.07159.x · Cited by 56
Self-citationAll Low-Density Lipoprotein Particles Are Not Created Equal
Krauss, R. M. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303458 · Cited by 55
Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease
Hayashi, T., Hirano, T., Taira, T., Tokuno, A., Mori, Y., Koba, S., & Adachi, M. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.03.015 · Cited by 53
Self-citationMethod for estimating high sdLDL-C by measuring triglyceride and apolipoprotein B levels
Hayashi, T., Koba, S., Ito, Y., & Hirano, T. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0417-6 · Cited by 51
Self-citationGeorgieva, A. M., van Greevenbroek, M. M. J., Krauss, R. M., Brouwers, M. C. G. J., Vermeulen, V. M. M.-J., Robertus-Teunissen, M. G., Kallen, C., & de Bruin, T. W. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000119681.47218.a4 · Cited by 45
Field, P., & Gibbons, G. F. (2000) · Metabolism · doi:10.1016/s0026-0495(00)80014-1 · Cited by 43
Kashiwazaki, K., Hirano, T., Yoshino, G., Kurokawa, M., Tajima, H., & Adachi, M. (1998) · Diabetes Care · doi:10.2337/diacare.21.11.2016 · Cited by 42
Self-citationHirano, T., Ookubo, K., Kashiwazaki, K., Tajima, H., Yoshino, G., & Adachi, M. (2000) · Clinica Chimica Acta · doi:10.1016/s0009-8981(00)00274-6 · Cited by 38
Self-citationKazumi, T., Hirano, T., Odaka, H., Ebara, T., Amano, N., Hozumi, T., Ishida, Y., & Yoshino, G. (1996) · Diabetes · doi:10.2337/diab.45.6.806 · Cited by 37
Self-citationVLDL production is decreased to a similar extent by acute portal vs. peripheral venous insulin
Lewis, G. F., Zinman, B., Uffelman, K. D., Szeto, L., Weller, B., & Steiner, G. A. (1994) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1994.267.4.e566 · Cited by 35
Seiichi, F., & Tsutomu, H. (1993) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(93)90172-6 · Cited by 34
Mori, Y., Hirano, T., Nagashima, M., Shiraishi, Y., Fukui, T., & Adachi, M. (2007) · Metabolism · doi:10.1016/j.metabol.2007.07.016 · Cited by 31
Self-citationCalabresi, L., Franceschini, G., Sirtori, M., GIANFRANCESCHI, G., Werba, J. P., & SIRTORI, C. (1990) · Atherosclerosis · doi:10.1016/0021-9150(90)90006-5 · Cited by 30
Campos, E. M., Kotite, L., Blanche, P. J., Mitsugi, Y., Frost, P. H., Masharani, U. B., Krauss, R. M., & Havel, R. J. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30142-5 · Cited by 28
Development of a homogeneous assay for measurement of high-density lipoprotein-subclass cholesterol
Ito, Y., Satoh, N., Ishii, T., Kumakura, J., & Hirano, T. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.09.009 · Cited by 26
Self-citationFukui, T., & Hirano, T. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej11-0329 · Cited by 20
Self-citationHirano, T., Takahashi, T., Saito, S., Tajima, H., Ebara, T., & Adachi, M. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.4.e665 · Cited by 19
Self-citationKaumi, T., Hirano, T., Odaka, H., Ebara, T., Amano, N., Hozumi, T., Ishida, Y., & Yoshino, G. M. (1996) · Diabetes · doi:10.2337/diabetes.45.6.806 · Cited by 19
Self-citationTakahashi, T., Hirano, T., Okada, K., & Adachi, M. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00202-6 · Cited by 18
Self-citationSuga, A., Hirano, T., Inoue, S., Tsuji, M., Osaka, T., Namba, Y., Miura, M., & Adachi, M. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.4.e650 · Cited by 18
Self-citationSeparation of VLDL subfractions by density gradient ultracentrifugation.
Zhao, S., Bastiaanse, E. M. L., Hau, M. F., Smelt, A. H. M., Leuven, J. A. G., van der Laarse, A., & Hooft, F. M. V. (1995) · PubMed · Cited by 16
Hirano, T., Hayashi, T., Adachi, M., Taira, T., & Hattori, H. (2007) · Metabolism · doi:10.1016/j.metabol.2006.11.002 · Cited by 12
Self-citation
Cited by
Poznyak, A., Grechko, A. V., Poggio, P., Myasoedova, V. A., Alfieri, V., & Orekhov, A. N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051835 · Cited by 1,163
“Diabetes-associated dyslipidemia received much attention during recent years and became the subject of numerous review papers [36,37].”
BackgroundJoseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Insulin resistance and cardiovascular disease
Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023) · Journal of International Medical Research · doi:10.1177/03000605231164548 · Cited by 385
“The sdLDL-C particles are particularly proatherogenic for various reasons: their smaller size facilitates their entrance into the vessel walls; they have impaired affinity with the LDL-C receptor; a longer half-life and lower resistance to oxidation.(127,128)”
BackgroundAthinarayanan, S. J., Adams, R. N., Hallberg, S. J., McKenzie, A. L., Bhanpuri, N. H., Campbell, W. W., Volek, J. S., Phinney, S. D., & McCarter, J. P. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00348 · Cited by 324
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
Metadata
- Authors
- Hirano, T.
- Affiliations
- SHOWA Medical University (JP)
- Corresponding author
- Hirano, Tsutomu
- ORCID
- Hirano, Tsutomu
- Venue
- Journal of Atherosclerosis and Thrombosis
- Publisher
- Japan Atherosclerosis Society
- Published
- 2018-09-01
- Volume
- 25
- Issue
- 9
- Pages
- 771-782
- ISSN
- 1340-3478 (ISSN-L)
- 1880-3873
- PMC
- PMC6143775
- OpenAlex
- W2820707192
- Cited by
- 552
- References
- 102
- Citations by year
- 2026: 65 · 2025: 90 · 2024: 81 · 2023: 86 · 2022: 88 · 2021: 70 · 2020: 46 · 2019: 21 · 2018: 4
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Journal of Atherosclerosis and Thrombosis (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- diabetic dyslipidemia, type 2 diabetes, triglyceride-rich lipoproteins, VLDL, small dense LDL, HDL2, HDL3 cholesterol, insulin resistance, hyperinsulinemia, lipoprotein lipase, atherosclerotic cardiovascular disease, diabetic nephropathy, plasma lipid profile
- MeSH terms
- Pioglitazone, Animals, Cholesterol, Chylomicrons, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Fatty Acids, Nonesterified, Glycated Hemoglobin, Humans, Insulin, Insulin Resistance, Lipoproteins, Cholesterol, HDL, Cholesterol, LDL, Lipoproteins, VLDL, Liver, Risk, Triglycerides, Cholesterol, VLDL, Dyslipidemias, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.